Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation

Denosumab is a potent osteoclast inhibitor targeted to prevent osteoporotic bone loss and thereby reduce fractures in the aging population. Recently, an elevated risk of rebound fractures following denosumab discontinuation was identified, unless patients were transitioned to an alternative antireso...

Descripción completa

Detalles Bibliográficos
Autores principales: Jähn-Rickert, Katharina, Wölfel, Eva M., Jobke, Björn, Riedel, Christoph, Hellmich, Maya, Werner, Mathias, McDonald, Michelle M., Busse, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243474/
https://www.ncbi.nlm.nih.gov/pubmed/32499755
http://dx.doi.org/10.3389/fendo.2020.00250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243474/
https://www.ncbi.nlm.nih.gov/pubmed/32499755
http://dx.doi.org/10.3389/fendo.2020.00250

Ejemplares similares